Daiichi Sankyo (OTCMKTS:DSNKY) Shares Up 5.2% – Should You Buy?

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) rose 5.2% on Monday . The company traded as high as $18.43 and last traded at $18.40. Approximately 3,199 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 343,306 shares. The stock had previously closed at $17.49.

Analyst Upgrades and Downgrades

DSNKY has been the subject of several research analyst reports. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Daiichi Sankyo presently has an average rating of “Reduce”.

Daiichi Sankyo Stock Performance

The firm has a market capitalization of $34.28 billion, a PE ratio of 21.40, a price-to-earnings-growth ratio of 2.48 and a beta of -0.11. The firm’s 50 day moving average price is $17.43 and its 200-day moving average price is $17.28. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.